Survival

Guideline Recommendations Offer No OS Benefit for Younger Patients With Rectal Cancer

Guideline Recommendations Offer No OS Benefit for Younger Patients With Rectal Cancer

A retrospective review of data from the National Cancer Data Base demonstrated that trends in rectal cancer may follow a pattern similar to that of colon cancer.

Certain Risk Factors May Decrease Overall Survival in Pediatric B-NHL

Certain Risk Factors May Decrease Overall Survival in Pediatric B-NHL

By

A new analysis of FAB/LMB 96 looked into factors associated with shortened OS among children and adolescents with B-NHL.

QOL, Fatigue, but Not Physical Performance, Return to Normal After AML Treatment

QOL, Fatigue, but Not Physical Performance, Return to Normal After AML Treatment

By

In a prospective, longitudinal study, researchers investigated the potential for quality of life, fatigue, and physical functioning to return to previous levels in patients with AML after treatment.

Radiotherapy Outcomes Improved When Breast Cancer CTCs Detectable 

Radiotherapy Outcomes Improved When Breast Cancer CTCs Detectable 

By

Researchers explored connections between overall survival and adjuvant radiotherapy when factoring in CTC status.

Overall Survival Benefit With Prostate Cancer Vaccine Not Duplicated in Phase 3 Trial

Overall Survival Benefit With Prostate Cancer Vaccine Not Duplicated in Phase 3 Trial

By

Latest findings do not confirm an overall survival (OS) benefit found in a previous randomized phase 2 trial.

No Improvement in OS, DFS With MP + Adjuvant ADT for High-Risk Prostate Cancer

No Improvement in OS, DFS With MP + Adjuvant ADT for High-Risk Prostate Cancer

By

The addition of mitoxantrone and prednisone (MP) to adjuvant androgen-deprivation therapy did not increase survival among patients with high-risk prostate cancer.

Dose-Dense Chemotherapy for Breast Cancer May Impair Lung Function

Dose-Dense Chemotherapy for Breast Cancer May Impair Lung Function

By

Long-term analysis determined the effect of postadjuvant dose-dense chemotherapy on DLCO among women with breast cancer.

Novel Agents Plus Paclitaxel, Carboplatin, Does Not Improve Survival in Endometrial Cancer

Novel Agents Plus Paclitaxel, Carboplatin, Does Not Improve Survival in Endometrial Cancer

By

A phase 2 study determined if adding bevacizumab or temsirolimus to PC, or an ixabepilone/carboplatin/bevacizumab combination will increase progression-free survival for women with advanced/recurrent endometrial cancer, compared with PC alone.

Low-fat Diet May Improve Overall Survival in Newly Diagnosed Breast Cancer

Low-fat Diet May Improve Overall Survival in Newly Diagnosed Breast Cancer

By

In a follow-up to the Women's Health Initiative study, researchers determined the effect of a low-fat diet on overall survival after a breast cancer diagnosis.

Primary Cytoreductive Surgery for HGSC Offers Better Survival Than Neoadjuvant Chemotherapy

Primary Cytoreductive Surgery for HGSC Offers Better Survival Than Neoadjuvant Chemotherapy

By

Researchers conducted a retrospective cohort analysis to examine patterns of clinical practice in the management of women with advanced HGSC.

Durable Response Achieved With Nivolumab in Untreated Melanoma Brain Metastases

Durable Response Achieved With Nivolumab in Untreated Melanoma Brain Metastases

By

In this phase 2 study, researchers randomly assigned 79 patients with immunotherapy-naive melanoma with brain metastases to receive either nivolumab plus ipilimumab or nivolumab alone.

Long-term Survival Improving Over Time in Advanced Hodgkin Lymphoma

Long-term Survival Improving Over Time in Advanced Hodgkin Lymphoma

By

A review of SEER data revealed trends in incidence of advanced Hodgkin lymphoma, discrepancies among subgroups, and survival over 3 decades.

Venetoclax Found Effective in Relapsed/Refractory Chronic Lymphocytic Leukemia

Venetoclax Found Effective in Relapsed/Refractory Chronic Lymphocytic Leukemia

By

A group of Australian researchers report study findings that demonstrate a significant improvement in PFS in patients with relapsed/refractory CLL treated with venetoclax plus rituximab compared with the standard care.

Insurance Type Influences Colon Cancer Survival

Insurance Type Influences Colon Cancer Survival

Researchers evaluated survival in patients with colon cancer, according to the type of insurance the patients held.

Redefining Prognosis for Hematologic Cancers in Older Adults by Age

Redefining Prognosis for Hematologic Cancers in Older Adults by Age

By

A report on how variations in the effects of geriatric syndromes and aging can affect treatment modality choices and outcomes for the eldest older adults with hematologic cancers.

Venetoclax plus rituximab increases progression-free survival in relapsed chronic lymphocytic leukemia

1. Patients with relapsed or remitting chronic lymphocytic leukemia (CLL) treated with venetoclax-rituximab had a greater 2-year progression-free survival rate compared to bendamustine-rituximab treated patients. 2. Progression-free survival rates were greater for venetoclax-rituximab patients in almost all subgroup analysis, including patients with chromosome 17p deletion. Evidence Rating Level: 1 (Excellent) Study Rundown: Curative treatment of relapsed []

Higher Socioeconomic Status Leads to Improved Survival Outcomes in Anal Cancer

Higher Socioeconomic Status Leads to Improved Survival Outcomes in Anal Cancer

By

A multivariable analysis revealed how median household income influences cancer-specific and overall survival among patients with squamous cell carcinoma of the anus.

Obesity, Male Gender May Improve Survival Outcomes with Targeted and Immunotherapy in Melanoma

Obesity, Male Gender May Improve Survival Outcomes with Targeted and Immunotherapy in Melanoma

By

A retrospective study evaluated the relationship of BMI with survival outcomes among patients with metastatic melanoma who received targeted therapy, immunotherapy, or chemotherapy.

Apalutamide Prolongs Time to Metastasis in Castration-resistant Prostate Cancer

Apalutamide Prolongs Time to Metastasis in Castration-resistant Prostate Cancer

By

SPARTAN phase 3 study shows that apalutamide prolongs metastasis-free survival and time to symptomatic progression compared with placebo among men with nonmetastatic CRPC.

Antibiotics May Reduce Treatment-Related Issues in Renal Cell Carcinoma

Antibiotics May Reduce Treatment-Related Issues in Renal Cell Carcinoma

By

Researchers evaluated the effect of antibiotics on treatment delays, interruptions, and dose reductions in patients with mRCC treated with a first-line VEGF-TKI and presented their results at the 2018 Genitourinary Cancers Symposium.

Breast Cancer Therapies Associated With Increased Risk for Cardiovascular Disease

Breast Cancer Therapies Associated With Increased Risk for Cardiovascular Disease

By

Advances in breast cancer treatment are improving outcomes for patients with the disease; however, treatments are increasing these patients' risk for cardiovascular diseases.

Depression Predictive of Poor Survival Outcomes in Head and Neck Cancer

Depression Predictive of Poor Survival Outcomes in Head and Neck Cancer

By

In this study, researchers sought to determine the effect depressive symptoms during treatment planning had on immediate and long-term outcomes for patients with head and neck cancer.

OS Similar With Gemcitabine Plus S-1 vs Standard Therapy for Biliary Tract Cancer

OS Similar With Gemcitabine Plus S-1 vs Standard Therapy for Biliary Tract Cancer

By

In a phase 3 study presented at the 2018 Gastrointestinal Cancers Symposium, researchers reported on OS outcomes with gemcitabine plus S-1 vs gemcitabine plus cisplatin in patients with advanced biliary tract cancer.

Capecitabine and Oxaliplatin as First and Second Line Treatment for Locally Advanced and Metastatic Pancreatic Ductal Adenocarcinoma

Capecitabine and Oxaliplatin as First and Second Line Treatment for Locally Advanced and Metastatic Pancreatic Ductal Adenocarcinoma

[Journal of Gastrointestinal Oncology] This research evaluates the use of capecitabine and oxaliplatin (CAPOX) for first or second-line treatment of locally advanced or metastatic PDAC.

Mortality Higher in Women With Breast Cancer and Comorbid Mental Illness

Mortality Higher in Women With Breast Cancer and Comorbid Mental Illness

By

In a retrospective study of SEER-Medicare data, researchers determined the survival outcomes of women with breast cancer and comorbid mental illness vs those without mental illness.

Survival Benefit in Advanced Melanoma With Pembrolizumab Versus Ipilimumab

Survival Benefit in Advanced Melanoma With Pembrolizumab Versus Ipilimumab

By

Fifty-five percent of patients treated with pembrolizumab survived through 24-months compared with 43% of patients treated with ipilimumab.

Adjuvant Endocrine Therapy Benefits Younger Women With ER+ Breast Cancer

Adjuvant Endocrine Therapy Benefits Younger Women With ER+ Breast Cancer

By

A comparison of adjuvant endocrine therapies showed one option provided greater reduction in disease recurrence among premenopausal women with ER+ breast cancer.

Prolonging Survival in MM: Daratumumab vs Pomalidomide Plus Dexamethasone

Prolonging Survival in MM: Daratumumab vs Pomalidomide Plus Dexamethasone

By

A head-to-head comparison investigated whether patients with multiple myeloma achieved greater prolongation in overall survival with daratumumab monotherapy or pomalidomide plus low-dose dexamethasone.

Reduced Delayed Intensification Impacts Risk of Pediatric ALL Relapse

Reduced Delayed Intensification Impacts Risk of Pediatric ALL Relapse

By

Improved survival in pediatric patients with standard-risk ALL has shifted the focus toward reducing treatment burden and toxicity; therefore, researchers sought to determine the effects of reduced DI chemotherapy on relapse and survival.

Drug Combination Does Not Extend Glioblastoma Survival

Drug Combination Does Not Extend Glioblastoma Survival

Lomustine plus bevacizumab may increase progression-free, but not overall, survival versus lomustine alone in progressive glioblastoma.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs